Exchange Traded Concepts LLC Has $847,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Exchange Traded Concepts LLC reduced its holdings in Becton, Dickinson and Company (NYSE:BDXFree Report) by 3.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,733 shares of the medical instruments supplier’s stock after selling 134 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Becton, Dickinson and Company were worth $847,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Livelsberger Financial Advisory bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company during the third quarter worth $33,000. Tompkins Financial Corp increased its holdings in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Sound Income Strategies LLC lifted its stake in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the period. Finally, Kennebec Savings Bank bought a new position in Becton, Dickinson and Company during the third quarter worth about $46,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $249.75 on Wednesday. The company has a fifty day moving average price of $228.56 and a 200 day moving average price of $233.31. The firm has a market cap of $72.43 billion, a PE ratio of 42.05, a PEG ratio of 1.72 and a beta of 0.39. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $250.91.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the company earned $3.42 earnings per share. Research analysts predict that Becton, Dickinson and Company will post 14.42 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.67%. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase program on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

BDX has been the subject of a number of recent analyst reports. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $283.00.

Check Out Our Latest Report on Becton, Dickinson and Company

Insider Buying and Selling

In related news, EVP Roland Goette sold 638 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 2,838 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total value of $633,810.54. Following the transaction, the executive vice president now directly owns 6,141 shares in the company, valued at $1,371,469.53. This trade represents a 31.61 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 9,844 shares of company stock worth $2,210,716. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.